JP2018514565A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514565A5
JP2018514565A5 JP2017556902A JP2017556902A JP2018514565A5 JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5 JP 2017556902 A JP2017556902 A JP 2017556902A JP 2017556902 A JP2017556902 A JP 2017556902A JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5
Authority
JP
Japan
Prior art keywords
depot
vaccine
seq
forming
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017556902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514565A (ja
JP6851983B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2016/050487 external-priority patent/WO2016176761A1/en
Publication of JP2018514565A publication Critical patent/JP2018514565A/ja
Publication of JP2018514565A5 publication Critical patent/JP2018514565A5/ja
Application granted granted Critical
Publication of JP6851983B2 publication Critical patent/JP6851983B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017556902A 2015-05-01 2016-04-27 デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法 Expired - Fee Related JP6851983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155677P 2015-05-01 2015-05-01
US62/155,677 2015-05-01
PCT/CA2016/050487 WO2016176761A1 (en) 2015-05-01 2016-04-27 Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines

Publications (3)

Publication Number Publication Date
JP2018514565A JP2018514565A (ja) 2018-06-07
JP2018514565A5 true JP2018514565A5 (https=) 2019-05-23
JP6851983B2 JP6851983B2 (ja) 2021-03-31

Family

ID=57217405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556902A Expired - Fee Related JP6851983B2 (ja) 2015-05-01 2016-04-27 デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法

Country Status (4)

Country Link
US (1) US20180162913A1 (https=)
EP (1) EP3288538A4 (https=)
JP (1) JP6851983B2 (https=)
WO (1) WO2016176761A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242883A4 (en) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
CN109328070A (zh) 2016-05-04 2019-02-12 免疫疫苗技术有限公司 包含两亲化合物、新抗原和疏水载体的疫苗组合物及其使用方法
EP3464360B1 (en) 2016-05-27 2025-11-12 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
CN109982715A (zh) 2016-09-27 2019-07-05 免疫疫苗技术有限公司 利用低剂量体积b细胞表位组合物以在受试人中诱导抗体免疫应答的方法
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
CN109456405B (zh) * 2017-09-06 2022-02-08 上海交通大学医学院附属仁济医院 一种去棕榈酰化pd-l1蛋白质及其制备方法和应用
AU2017438994A1 (en) * 2017-11-09 2020-05-28 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
CN107988373A (zh) * 2018-01-10 2018-05-04 上海交通大学医学院附属仁济医院 用于预测癌症免疫治疗效果的生物标志物、试剂盒与应用
WO2019178677A1 (en) * 2018-03-20 2019-09-26 Immunovaccine Technologies Inc. Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodes
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
US20220125903A1 (en) * 2018-11-19 2022-04-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
WO2024186623A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions
WO2024186646A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
JP4516916B2 (ja) * 2003-07-11 2010-08-04 昇志 佐藤 リビン由来のｈｌａ−ａ２４結合性癌抗原ペプチド
US7749520B2 (en) * 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
KR20070101341A (ko) * 2005-02-01 2007-10-16 메디바스, 엘엘씨 백신 전달 조성물 및 사용 방법
US7947286B2 (en) * 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20090092635A1 (en) * 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
WO2009146523A1 (en) * 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
WO2011120045A1 (en) * 2010-03-26 2011-09-29 Emergent Product Development Gaithersburg Inc. Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
WO2014055289A1 (en) * 2012-10-01 2014-04-10 Thomas Jefferson University Immunization with rabies virus vector expressing foreign protein antigen
CA2908042C (en) * 2013-03-27 2023-01-31 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2018514565A5 (https=)
Yang et al. Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases
Moni et al. Advancements in vaccine adjuvants: the journey from alum to nano formulations
Gote et al. A comprehensive review of mRNA vaccines
Facciolà et al. An overview of vaccine adjuvants: current evidence and future perspectives
Tan et al. Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants
Kaurav et al. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage
TWI672149B (zh) 改良之疫苗組成物及使用方法
Gomes et al. Harnessing nanoparticles for immunomodulation and vaccines
Cunningham et al. Vaccine development: From concept to early clinical testing
Deng et al. Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice
JP2015522580A5 (https=)
Martiñón et al. Chemical and immunological characteristics of aluminum‐based, oil‐water emulsion, and bacterial‐origin adjuvants
Barnier-Quer et al. Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators
Alving et al. Adjuvants for human vaccines
Goetz et al. Vaccine adjuvants for infectious disease in the clinic
Jabbal-Gill Nasal vaccine innovation
JP2014520807A5 (https=)
JP2018534304A5 (https=)
Atmar et al. Adjuvants for pandemic influenza vaccines
Even-Or et al. Adjuvanted influenza vaccines
Dowling et al. Pediatric vaccine adjuvants: components of the modern vaccinologist’s toolbox
RU2006139424A (ru) Вакцины
JP2014522842A5 (https=)
Li et al. Adjuvantation of influenza vaccines to induce cross-protective immunity